CNTO 6785: Phase II started

Johnson & Johnson's Janssen Biotech Inc. subsidiary began a double-blind, placebo-controlled, international Phase II trial to evaluate 15, 50, 100 and 200 mg subcutaneous CNTO 6785 every 4 weeks for 2...